DE69504637D1 - Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten - Google Patents
Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheitenInfo
- Publication number
- DE69504637D1 DE69504637D1 DE69504637T DE69504637T DE69504637D1 DE 69504637 D1 DE69504637 D1 DE 69504637D1 DE 69504637 T DE69504637 T DE 69504637T DE 69504637 T DE69504637 T DE 69504637T DE 69504637 D1 DE69504637 D1 DE 69504637D1
- Authority
- DE
- Germany
- Prior art keywords
- estrogen
- treatment
- neoplasms
- diseases
- neoplastic disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
- C07D209/28—1-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20005794A | 1994-02-22 | 1994-02-22 | |
US36204694A | 1994-12-22 | 1994-12-22 | |
PCT/US1995/001372 WO1995022524A1 (en) | 1994-02-22 | 1995-01-31 | Novel indole derivatives useful to treat estrogen-related neoplasms and disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69504637D1 true DE69504637D1 (de) | 1998-10-15 |
DE69504637T2 DE69504637T2 (de) | 1999-05-06 |
Family
ID=26895427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69504637T Expired - Lifetime DE69504637T2 (de) | 1994-02-22 | 1995-01-31 | Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten |
Country Status (17)
Country | Link |
---|---|
US (1) | US5877202A (de) |
EP (1) | EP0746544B1 (de) |
JP (1) | JP3536258B2 (de) |
KR (1) | KR100362864B1 (de) |
CN (1) | CN1141627A (de) |
AT (1) | ATE170839T1 (de) |
AU (1) | AU680740B2 (de) |
CA (1) | CA2183731C (de) |
DE (1) | DE69504637T2 (de) |
DK (1) | DK0746544T3 (de) |
ES (1) | ES2122555T3 (de) |
FI (1) | FI963272A0 (de) |
HU (1) | HUT76133A (de) |
IL (1) | IL112700A0 (de) |
NO (1) | NO963483L (de) |
NZ (1) | NZ281431A (de) |
WO (1) | WO1995022524A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW397821B (en) * | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
AU6015098A (en) * | 1997-02-24 | 1998-09-09 | Cornell Research Foundation Inc. | Method of screening agents as candidates for drugs or sources of drugs |
US6150395A (en) * | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
US6069153A (en) * | 1998-05-12 | 2000-05-30 | American Home Products Corporation | Indenoindoles and benzocarbazoles as estrogenic agents |
US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
JP2002515484A (ja) * | 1998-05-15 | 2002-05-28 | アメリカン・ホーム・プロダクツ・コーポレイション | 2−フェニルインドール化合物およびエストロゲン製剤からなる組成物 |
US6207700B1 (en) * | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
US6159959A (en) * | 1999-05-06 | 2000-12-12 | American Home Products Corporation | Combined estrogen and antiestrogen therapy |
BR0013943A (pt) * | 1999-09-13 | 2002-05-14 | American Home Prod | Conjugados de glicopiranosìdeos de 2-(4-hidróxi-fenil)-1-[4-(2-amin-1-il-etóxi)-benzil]-1h-indo l-5-óis |
DE19962300A1 (de) * | 1999-12-23 | 2001-06-28 | Asta Medica Ag | Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung |
WO2001058869A2 (en) * | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
US6326501B1 (en) * | 2000-04-19 | 2001-12-04 | Hoffmann-La Roche Inc. | Methylation of indole compounds using dimethyl carbonate |
AU2002211828A1 (en) * | 2000-10-02 | 2002-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US20030130199A1 (en) * | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
FR2842526B1 (fr) | 2002-07-16 | 2007-07-13 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments |
CN1791402A (zh) * | 2003-03-27 | 2006-06-21 | 麦克公司 | 治疗眼高压的眼科组合物 |
CA2562783A1 (en) | 2004-04-26 | 2005-12-01 | Vanderbilt University | Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity |
WO2007013872A2 (en) * | 2004-07-22 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Sensors employing single-walled carbon nanotubes |
WO2007062399A2 (en) | 2005-11-23 | 2007-05-31 | The Board Of Regents Of The University Of Texas System | Oncogenic ras-specific cytotoxic compound and methods of use thereof |
CA2777782C (en) | 2009-10-15 | 2016-06-28 | Children's Medical Center Corporation | Sepiapterin reductase inhibitors for the treatment of pain |
AU2011296103B2 (en) | 2010-08-30 | 2016-05-05 | Arzeda Corp. | Fermentation route for the production of levulinic acid, levulinate esters, valerolactone, and derivatives thereof |
US9346803B2 (en) | 2011-10-17 | 2016-05-24 | Vanderbilt University | Indomethacin analogs for the treatment of castrate-resistant prostate cancer |
CN107011229B (zh) | 2012-01-06 | 2019-11-05 | 诺华股份有限公司 | 杂环化合物和它们的使用方法 |
WO2013131235A1 (zh) * | 2012-03-05 | 2013-09-12 | 大连理工大学 | 一类以萘为母体的双光子荧光探针、其制备方法及应用 |
TW202222786A (zh) | 2016-02-01 | 2022-06-16 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
WO2018125992A1 (en) * | 2016-12-28 | 2018-07-05 | Promega Corporation | Functionalized nanoluc inhibitors |
EP4334285A1 (de) * | 2021-05-05 | 2024-03-13 | Kare Chemical Technologies Inc. | Katalytische tryptamin-verfahren und vorläufer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1482845A (fr) * | 1964-12-31 | 1967-06-02 | Merck & Co Inc | Composés de l'indol |
DK0431520T3 (da) * | 1989-12-04 | 1995-04-10 | Searle & Co | Heterocycliske acylaminodiol-beta-aminosyrederivater |
CA2074357A1 (fr) * | 1990-03-07 | 1991-09-08 | Jean-Dominique Bourzat | Derives de glycinamide, leur preparation et les medicaments les contenant |
US5312928A (en) * | 1991-02-11 | 1994-05-17 | Cambridge Neuroscience | Calcium channel antagonists and methodology for their identification |
EP0639567A1 (de) * | 1992-05-08 | 1995-02-22 | Otsuka Pharmaceutical Factory, Inc. | Indol-derivate |
JPH0835029A (ja) * | 1994-07-19 | 1996-02-06 | Toyota Motor Corp | 高強度高延性鋳造アルミニウム合金およびその製造方法 |
-
1995
- 1995-01-31 KR KR1019960704579A patent/KR100362864B1/ko not_active IP Right Cessation
- 1995-01-31 CA CA002183731A patent/CA2183731C/en not_active Expired - Lifetime
- 1995-01-31 AT AT95910164T patent/ATE170839T1/de not_active IP Right Cessation
- 1995-01-31 DK DK95910164T patent/DK0746544T3/da active
- 1995-01-31 DE DE69504637T patent/DE69504637T2/de not_active Expired - Lifetime
- 1995-01-31 ES ES95910164T patent/ES2122555T3/es not_active Expired - Lifetime
- 1995-01-31 HU HU9602299A patent/HUT76133A/hu unknown
- 1995-01-31 AU AU18373/95A patent/AU680740B2/en not_active Ceased
- 1995-01-31 EP EP95910164A patent/EP0746544B1/de not_active Expired - Lifetime
- 1995-01-31 CN CN95191750A patent/CN1141627A/zh active Pending
- 1995-01-31 JP JP52182295A patent/JP3536258B2/ja not_active Expired - Lifetime
- 1995-01-31 WO PCT/US1995/001372 patent/WO1995022524A1/en active IP Right Grant
- 1995-01-31 NZ NZ281431A patent/NZ281431A/en unknown
- 1995-02-20 IL IL11270095A patent/IL112700A0/xx unknown
-
1996
- 1996-01-31 US US08/594,505 patent/US5877202A/en not_active Expired - Lifetime
- 1996-08-21 NO NO963483A patent/NO963483L/no unknown
- 1996-08-21 FI FI963272A patent/FI963272A0/fi unknown
Also Published As
Publication number | Publication date |
---|---|
ATE170839T1 (de) | 1998-09-15 |
ES2122555T3 (es) | 1998-12-16 |
US5877202A (en) | 1999-03-02 |
FI963272A (fi) | 1996-08-21 |
NO963483L (no) | 1996-10-22 |
CA2183731A1 (en) | 1995-08-24 |
HUT76133A (en) | 1997-06-30 |
JPH09509169A (ja) | 1997-09-16 |
AU680740B2 (en) | 1997-08-07 |
FI963272A0 (fi) | 1996-08-21 |
DE69504637T2 (de) | 1999-05-06 |
CA2183731C (en) | 2000-03-21 |
DK0746544T3 (da) | 1999-06-07 |
IL112700A0 (en) | 1995-05-26 |
CN1141627A (zh) | 1997-01-29 |
JP3536258B2 (ja) | 2004-06-07 |
NZ281431A (en) | 1997-09-22 |
EP0746544B1 (de) | 1998-09-09 |
EP0746544A1 (de) | 1996-12-11 |
KR100362864B1 (ko) | 2003-04-16 |
AU1837395A (en) | 1995-09-04 |
HU9602299D0 (en) | 1996-10-28 |
NO963483D0 (no) | 1996-08-21 |
WO1995022524A1 (en) | 1995-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69504637D1 (de) | Indolderivate zur behandlung von östrogenabhängigen neoplasmen und krankheiten | |
DE69521620T2 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
DE69625691T2 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
DE69921156D1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
ATE224189T1 (de) | Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit | |
ATE468137T1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
ATE282413T1 (de) | Verwendung von tempol zur behandlung von essentiellem hochdruck | |
ATE230417T1 (de) | Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien | |
DE69831406D1 (de) | Verwendung von thiazolidinedion-derivaten zur behandlung des polyzystischen ovarien syndroms und des schwangerschaftsdiabetes | |
DE69807115D1 (de) | Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms | |
ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
DE69413829T2 (de) | Antiglucocorticoidsteroide zur behandlung von angststörungen | |
ATE201992T1 (de) | Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen | |
DE69725879D1 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
ATE210447T1 (de) | Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen | |
ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
ATE190839T1 (de) | Verwendung von prodelphidinen zur behandlung von arthrose | |
DE60005952T8 (de) | Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten | |
ATA901396A (de) | Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten | |
ATE293994T1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
RU94000387A (ru) | Способ лечения врожденного вывиха надколенника | |
ATE168697T1 (de) | Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen | |
ATE279214T1 (de) | Auf bibapcitide gegründete pharmaceutische zusammensetzungen für bildgebung und behandlung von thromben | |
ATE236640T1 (de) | Budesonid zur behandlung von cholestatischen lebererkrankungen | |
DE60012163D1 (de) | Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: AVENTIS INC. (N.D.GES.D. STAATES PENNSYLVANIA), GR |
|
8327 | Change in the person/name/address of the patent owner |
Owner name: AVENTISUB II INC., GREENVILLE, DEL., US |